Use of anthracycline antibiotics in preparation of medicines for treating age-related macular degeneration

A technology of antibiotics and anthracyclines, which is applied in the application field of anthracyclines in the preparation of drugs for the treatment of age-related macular degeneration, which can solve the problems of not finding effective preventive measures, cost promotion obstacles, and the curative effect depends on continuous repeated medication And other issues

Active Publication Date: 2013-05-08
张雅珍
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the curative effect of anti-vascular endothelial growth factor drugs is acceptable, the maintenance of the curative effect depends on continuous repeated administration, and the high cost has become an obstacle to their promotion
[0005] 2. Interferon
As a result, no safe, effective, and economical treatments have been found to improve vision or prevent vision deterioration, nor have effective preventive measures been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of anthracycline antibiotics in preparation of medicines for treating age-related macular degeneration
  • Use of anthracycline antibiotics in preparation of medicines for treating age-related macular degeneration
  • Use of anthracycline antibiotics in preparation of medicines for treating age-related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] ① Take 300mg of sebacic anhydride-ethylene glycol copolymer (PSA-PEG) and add it to 3ml of acetone and ethanol (7:3) to prepare an organic phase;

[0027] ② Add 60 mg of daunorubicin to the organic phase prepared in ① and sonicate;

[0028] ③ Take propylene glycol block polyether and Tween 80 (1:1) to make a 3% aqueous solution containing an emulsifier, and add dextran 70 to it to adjust the pH of the solution to 8;

[0029] ④ adding dropwise to the organic phase obtained in step ① to the external water obtained in ③;

[0030] ⑤Remove the organic solvent and collect by centrifugation to obtain a nanoparticle solution.

Embodiment 2

[0032] ①Dissolve 800mg of doxorubicin and lactic acid-glycolic acid-ethylene glycol copolymer (PLGA-PEG) with 3ml of dichloromethane and 1ml of DMSO in a water bath at 30°C and stir at high speed;

[0033] ② Add ① to 1% polyvinyl alcohol to 100ml, and mix well;

[0034] ③ Stir and volatilize at room temperature for 2 hours to obtain a nanoparticle solution;

[0035] ④ Collect the obtained nanoparticles after centrifugation at 4°C for 20 minutes;

[0036] ⑤ Wash the product obtained in ④ three times with double distilled water to obtain the drug-loaded nanoparticles.

Embodiment 3

[0038] ① Take 300mg of poly sebacic anhydride (PSA) and add it to 3ml of dichloromethane to prepare an organic phase;

[0039] ②Add 40mg of idarubicin to the organic phase prepared in ①;

[0040] ③ Take propylene glycol block polyether and Tween 80 (1:1) to make an aqueous solution containing 4% emulsifier, and add dextran 70 to it to adjust the pH of the solution to 8;

[0041] ④ using the nano-sedimentation method to drop the organic phase prepared in step ① into the aqueous phase prepared in ③;

[0042] ⑤ Stir to remove the organic solvent to obtain a nanoparticle solution, which is collected by centrifugation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses a new use of a series of anthracycline antibiotics and medicinal salts thereof. The new use is the use in the preparation of medicines for treating age-related macular degeneration (AMD). Researches in the invention prove that the AMD symptom treatment effect can be performed through inhibiting HIF-1 after the small-dosage multi-time intraocular administration of the common powder injection of the anthracycline antibiotics and the one-time intraocular administration of a polymer prepared long-acting micro-balloon or nano-preparation and a hydrogel long-acting preparation, and no side effects comprising retinopathy or the like are caused. The medicines can continuously act for two months because the slow release administration effect mode can be applied.

Description

technical field [0001] The present invention relates to a series of new pharmaceutical applications of traditional antineoplastic drugs anthracyclines, and the new applications relate to the treatment of age-related macular degeneration. Background technique [0002] Age-related macular degeneration (AMD) is an age-related, blinding eye disease and one of the main causes of irreversible visual impairment in the elderly. Of the two types of AMD, dry and wet, wet AMD, also known as neovascular AMD, is the more serious condition, causing loss of two-thirds of central vision. The main cause of blindness in wet AMD is the formation of choroidal neovascularization (CNV), which can lead to vascular leakage. This painless process develops rapidly and can lead to complete loss of retinal function in the corresponding area, eventually leading to visual impairment and even blindness. [0003] At present, the drugs for the treatment of AMD symptoms mainly include the following types: ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/7048A61K31/706A61K31/7056A61K31/7042A61K31/136A61P27/02
Inventor 张雅珍李铁力白毅
Owner 张雅珍
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap